Form 8-K - Current report:
SEC Accession No. 0001193125-24-014226
Filing Date
2024-01-24
Accepted
2024-01-24 16:10:55
Documents
12
Period of Report
2024-01-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d112633d8k.htm   iXBRL 8-K 26146
  Complete submission text file 0001193125-24-014226.txt   144477

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sage-20240122.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20240122_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20240122_pre.xml EX-101.PRE 10810
6 EXTRACTED XBRL INSTANCE DOCUMENT d112633d8k_htm.xml XML 3291
Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address 215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 24556514
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)